Amgen Forecast, price target & analysts
Amgen Target price 2025 - Analyst rating & recommendation
Amgen Classifications & Recommendation:
Amgen Price Target
| Target Price | $321.30 |
| Price | $295.27 |
| Potential | 8.82% |
| Number of Estimates | 30 |
| 30 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $321.30. This is 8.82% higher than the current stock price. The highest price target is $420.00 42.24% , the lowest is $186.85 36.72% . | |
| A rating was issued by 39 analysts: 21 Analysts recommend Amgen to buy, 15 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 8.82% . Most analysts recommend the Amgen stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
33 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $36.0b . This is 5.52% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $37.7b 10.59% , the lowest is $33.8b 0.83% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $33.4b | 18.57% |
|---|---|---|
| 2025 | $36.0b | 7.73% |
| 2026 | $36.6b | 1.78% |
| 2027 | $37.8b | 3.20% |
| 2028 | $37.5b | 0.82% |
| 2029 | $38.4b | 2.48% |
| 2032 | $43.2b | 2.15% |
17 Analysts have issued an Amgen EBITDA forecast 2025. The average Amgen EBITDA estimate is $20.8b . This is 46.43% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $22.3b 57.36% , the lowest is $18.4b 29.86% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $15.3b | 85.55% |
|---|---|---|
| 2025 | $20.8b | 36.23% |
| 2026 | $20.5b | 1.29% |
| 2027 | $20.3b | 0.82% |
| 2028 | $18.8b | 7.32% |
| 2029 | $18.6b | 1.56% |
| 2032 | $19.7b | 3.97% |
EBITDA Margin
| 2024 | 45.63% | 56.49% |
|---|---|---|
| 2025 | 57.69% | 26.44% |
| 2026 | 55.95% | 3.02% |
| 2027 | 53.77% | 3.90% |
| 2028 | 50.25% | 6.55% |
| 2029 | 48.27% | 3.94% |
| 2032 | 45.63% | 6.00% |
34 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $11.5b . This is 93.04% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $12.3b 107.35% , the lowest is $10.6b 78.61% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $4.1b | 39.11% |
|---|---|---|
| 2025 | $11.5b | 180.03% |
| 2026 | $11.8b | 2.97% |
| 2027 | $12.4b | 4.76% |
| 2028 | $10.5b | 14.93% |
| 2029 | $12.1b | 15.13% |
| 2032 | $15.5b | 3.24% |
Net Margin
| 2024 | 12.24% | 48.64% |
|---|---|---|
| 2025 | 31.81% | 159.96% |
| 2026 | 32.18% | 1.16% |
| 2027 | 32.66% | 1.49% |
| 2028 | 28.02% | 14.21% |
| 2029 | 31.48% | 12.35% |
| 2032 | 35.81% | 1.07% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
34 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $21.30 . This is 94.34% higher than earnings per share in the financial year 2024. The highest EPS forecast is $22.88 108.76% , the lowest is $19.71 79.84% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $7.56 | 39.47% |
|---|---|---|
| 2025 | $21.30 | 181.75% |
| 2026 | $21.93 | 2.96% |
| 2027 | $22.98 | 4.79% |
| 2028 | $19.55 | 14.93% |
| 2029 | $22.50 | 15.09% |
| 2032 | $28.76 | 3.23% |
P/E ratio
| Current | 26.94 | 49.91% |
|---|---|---|
| 2025 | 13.86 | 48.55% |
| 2026 | 13.46 | 2.89% |
| 2027 | 12.85 | 4.53% |
| 2028 | 14.34 | 11.60% |
| 2029 | 12.46 | 13.11% |
| 2032 | 10.27 | 3.11% |
Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 5.76 and an P/S ratio of 4.41 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 6.08 | 14.61% |
|---|---|---|
| 2025 | 5.76 | 5.30% |
| 2026 | 5.66 | 1.75% |
| 2027 | 5.48 | 3.10% |
| 2028 | 5.31 | 3.07% |
| 2029 | 5.19 | 2.42% |
| 2032 | 4.80 | 2.10% |
P/S ratio
| Current | 4.65 | 13.70% |
|---|---|---|
| 2025 | 4.41 | 5.23% |
| 2026 | 4.33 | 1.75% |
| 2027 | 4.20 | 3.10% |
| 2028 | 4.02 | 4.26% |
| 2029 | 3.92 | 2.42% |
| 2032 | 3.68 | 2.10% |
Current Amgen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Jun 27 2025 |
| Cantor Fitzgerald |
Neutral
➜
Neutral
|
Unchanged | Jun 24 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | May 16 2025 |
| Mizuho |
Neutral
➜
Neutral
|
Unchanged | May 07 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | May 02 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | May 02 2025 |
| Cantor Fitzgerald |
➜
Overweight
|
Initiated | Apr 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Jun 27 2025 |
|
Unchanged
Cantor Fitzgerald:
Neutral
➜
Neutral
|
Jun 24 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
May 16 2025 |
|
Unchanged
Mizuho:
Neutral
➜
Neutral
|
May 07 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
May 02 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
May 02 2025 |
|
Initiated
Cantor Fitzgerald:
➜
Overweight
|
Apr 22 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
